|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | ICOS-Texas Biotechnology |
|---|---|
| Collaborators: |
ICOS Corporation Texas Biotechnology Corporation |
| Information provided by: | ICOS-Texas Biotechnology |
| ClinicalTrials.gov Identifier: | NCT00034307 |
Purpose
This is a clinical research study designed to evaluate an investigational new medication called sitaxsentan for the treatment of pulmonary arterial hypertension (patients with NYHA functional class II, III or IV). The purpose of this study is to evaluate the safety and effectiveness of two different doses of sitaxsentan, compared to placebo (inactive treatment) for the treatment of pulmonary arterial hypertension. Patients who complete this trial may be eligible to take part in an extension trial (Protocol FPH01-X). Eligible patients who receive placebo in the 12-week study cross over to receive sitaxsentan for the extension trial.
| Condition | Intervention | Phase |
|---|---|---|
|
Pulmonary Hypertension |
Drug: sitaxsentan sodium |
Phase II Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension |
Eligibility| Ages Eligible for Study: | 16 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Hide Study Locations| United States, California | |
| University of California, San Francisco | |
| San Francisco, California, United States, 94143 | |
| Harbor-UCLA Medical Center | |
| Torrance, California, United States, 90502 | |
| University of Southern California Hospital, Ambulatory Health Sciences | |
| Los Angeles, California, United States, 90033 | |
| United States, Colorado | |
| University of Colorado/ Health Science Center | |
| Denver, Colorado, United States, 80262 | |
| The Children's Hospital | |
| Denver, Colorado, United States, 80218 | |
| United States, Georgia | |
| Medical College of Georgia | |
| Augusta, Georgia, United States, 30912 | |
| Emory University Hospital - McKelvey Lung Transplantation Center | |
| Atlanta, Georgia, United States, 30322 | |
| Dekalb Medical Center | |
| Decatur, Georgia, United States, 30033 | |
| United States, Illinois | |
| Rush Heart Institute, Center for Pulmonary Heart Disease, Rush-Presbyterian-St. Luke's Medical Center | |
| Chicago, Illinois, United States, 60612 | |
| United States, Louisiana | |
| LSU - School of Medicine | |
| New Orleans, Louisiana, United States, 70112 | |
| United States, Maine | |
| Maine Medical Center | |
| Portland, Maine, United States, 04102 | |
| United States, Maryland | |
| John Hopkins Hospital | |
| Baltimore, Maryland, United States, 21287 | |
| United States, Massachusetts | |
| Massachusetts General Hospital | |
| Boston, Massachusetts, United States, 02114 | |
| United States, Michigan | |
| University of Michigan Hospital, Division of Cardiology | |
| Ann Arbor, Michigan, United States, 48109 | |
| United States, Minnesota | |
| Mayo Clinic - Division of Cardiovascular Disease | |
| Rochester, Minnesota, United States, 55905 | |
| United States, New York | |
| Columbia Presbyterian Medical Center | |
| New York, New York, United States, 10032 | |
| United States, North Carolina | |
| Duke University Medical Center | |
| Durham, North Carolina, United States, 27710 | |
| United States, Ohio | |
| Division of Cardiology - The Ohio State University Medical Center | |
| Columbus, Ohio, United States, 43210 | |
| The Cleveland Clinic Foundation, Department of Pulmonary and Critical Care | |
| Cleveland, Ohio, United States, 44195 | |
| United States, Oregon | |
| Oregon Health Sciences | |
| Portland, Oregon, United States, 97201 | |
| United States, Pennsylvania | |
| University of Pittsburgh Medical Center, CHF/Transplantation Cardiology | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| United States, Rhode Island | |
| Pulmonary Division - Rhode Island Hospital | |
| Providence, Rhode Island, United States, 02903 | |
| United States, Tennessee | |
| Vanderbilt University Medical Center | |
| Nashville, Tennessee, United States, 37232 | |
| United States, Texas | |
| Baylor College of Medicine Pulmonary & Critical Care Section | |
| Houston, Texas, United States, 77030 | |
| United States, Wisconsin | |
| University of Wisconsin Medical School | |
| Milwaukee, Wisconsin, United States, 53215 | |
| Canada, Quebec | |
| SMBD Jewish General Hospital | |
| Montreal, Quebec, Canada, H3T 1E2 | |
| Study Director: | Lyn Frumkin, M.D., Ph.D. | ICOS Corporation |
More Information
| Study ID Numbers: | FPH01/FPH01-X |
| Study First Received: | April 24, 2002 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00034307 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Respiratory Tract Diseases Hypertension, Pulmonary Lung Diseases |
Vascular Diseases Cardiovascular Diseases Hypertension |